Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.

Insights

Equity compensation analyst

Director received 25,000 stock options as routine equity compensation.

The filing shows Medicus Pharma Ltd. director Cathy McMorris Rodgers was granted stock options for 25,000 common shares. The options have a $0.50 exercise price and expire on March 27, 2031, with no purchase price at grant.

This is a grant/award acquisition, not an open-market trade, so it mainly reflects the company’s equity compensation structure. After the grant, she holds options for 25,000 shares directly, with no additional derivative positions listed in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rodgers Cathy McMorris

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

Key Figures

Stock options granted: 25,000 options Exercise price: $0.50 per share Expiration date: March 27, 2031 +1 more

4 metrics

Stock options granted 25,000 options Grant to director on March 30, 2026

Exercise price $0.50 per share Stock option strike price

Expiration date March 27, 2031 Option term end date

Total options after grant 25,000 options Holdings following transaction

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "0.5000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-03-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodgers Cathy McMorris

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Cathy McMorris Rodgers	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Medicus Pharma (MDCX) disclose about Cathy McMorris Rodgers in this Form 4?

Medicus Pharma disclosed that director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at a $0.50 exercise price and represent equity compensation rather than an open-market share purchase or sale.

How many Medicus Pharma (MDCX) stock options were granted to the director?

The director received 25,000 stock options, each tied to one common share of Medicus Pharma. This entire amount is new derivative equity, and following the transaction she holds options for 25,000 shares directly according to the filing details.

What is the exercise price and expiration date of the Medicus Pharma options?

The stock options granted have an exercise price of $0.50 per share and an expiration date of March 27, 2031. This means the director can choose to buy shares at $0.50 any time before that expiration, subject to applicable vesting terms not detailed here.

Was the Medicus Pharma Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant/award acquisition of stock options, not an open-market stock purchase or sale. The director did not pay for shares at grant; instead, she received options giving the right to buy 25,000 shares later at $0.50 per share.

How does this Form 4 affect Cathy McMorris Rodgers’ holdings in Medicus Pharma?

After the grant, the filing shows she holds 25,000 stock options directly, each for one common share. No additional derivative positions are listed, so this award establishes her visible option position based on this specific Form 4 disclosure alone.